Ignitis Group’s net-zero targets receive validation from Science Based Targets initiative

Darius Maikštėnas CEO
Darius Maikštėnas CEO
0Comments

Ignitis Group, a company focused on renewable energy, has announced that the Science Based Targets initiative (SBTi) has validated and published its long-term net-zero and revalidated near-term greenhouse gas emission reduction targets. The group aims to achieve net-zero emissions across its value chain by 2040.

The SBTi evaluated Ignitis Group’s targets against their Net-Zero Standard Criteria and Near-Term Target Criteria and Recommendations. “The SBTi’s Target Validation Team has classified the Group’s scope 1 and 2 near-term target ambition and has determined that it is in line with a 1.5°C trajectory,” according to the announcement. Additionally, “the Target Validation Team has also evaluated the Group’s scope 1, 2, and 3 long-term target ambition, and determined that the long-term targets are aligned with the SBTi’s 1.5° C mitigation pathways for reaching net-zero by 2050 or sooner.”

To meet these goals, Ignitis Group plans to reduce emissions from its operations while engaging partners, suppliers, and customers. Planned measures include increasing green capacities, raising the share of green electricity in operations and sales, encouraging customer transitions from natural gas to electricity, reducing network losses, and upgrading its vehicle fleet with electric vehicles.

The group’s commitment to achieving net-zero emissions began in 2019 after joining the Business Ambition for a 1.5° C initiative.

SBTi is an organization dedicated to corporate climate action worldwide. It provides standards, tools, and guidance for companies to set greenhouse gas emission reduction targets aligned with global efforts to keep temperature rises below catastrophic levels.

More information about science-based targets can be found on both the SBTi website and Ignitis Group’s website.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.